Allotrope Foundation Releases Allotrope Framework 1.0
News Sep 30, 2015
The September internal release package includes version 1.0 of the Allotrope Data Format (ADF), the Application Programming Interfaces, (APIs), and the Allotrope Foundation Taxonomies (AFTs), marking the successful completion of the early phases of development. Designed for Allotrope Foundation by OSTHUS, a leading information management and technology services firm, the Allotrope Framework is an advanced data architecture that facilitates the creation, use and exchange of laboratory data by standardizing data representation across proprietary equipment and software.
Realizing the Vision
Members of Allotrope Foundation in collaboration with members of the Allotrope Partner Network have already begun to implement software solutions that integrate the Allotrope Framework into their laboratory workflows and enable adoption of the Allotrope Data Format, the cornerstone of the Allotrope Framework that enables software to access any data from any analytical instrument regardless of manufacturer or software version.
“The progress on the Allotrope Framework to date has shown significant promise in developing the tools that provide a standard file format and terminology for describing the data and workflow of the analytical laboratory in the software used to generate and analyze that data” said Dr. Dana Vanderwall, Associate Director, Cheminformatics at Bristol-Myers Squibb. “We have initiated a project to develop a standard platform for the planning, execution, analysis and reporting of analytical chemistry across Discovery Research at Bristol-Myers Squibb that will reduce the friction in the process of using data for decision making and insight- by leveraging the Allotrope Framework as a fundamental part of the infrastructure.”
GlaxoSmithKline (GSK) will implement the Allotrope Framework for use in drug substance release and stability testing in research and development (R&D) as a first step towards wider integration into multiple workflows across R&D and Manufacturing environments. The Allotrope Framework and Allotrope Data Format will be key enablers to drive automation and enhancement of data quality, compliance and integrity. GSK’s integration project encompasses the entire data lifecycle, including sample receipt, analysis, review and approval and long-term preservation. “Every decision we make about our products is based on data. To deliver safe and efficacious medicines to the patient, we must be confident in the quality and integrity of our data. Our integration project with Allotrope Foundation will deliver standard metadata and data stored in a standard format, addressing the root cause of our data challenges and revolutionizing the way we generate, access and use data to make decisions and deliver our pipeline of medicines.” Dr. Annette Doherty, Senior Vice President, Product Development & Supply.
Roadmap for the Allotrope Framework
The development of the Allotrope Framework is an ongoing project. In addition to the V1.0 elements of the ADF, APIs, and AFTs, the design of the Allotrope Framework includes a comprehensive Metadata Repository built on the Taxonomies and a more complete range of API functionality in the form of the Class Libraries. The generally available release of the full Framework is scheduled for the fourth quarter of 2016.
The Genes That Make Quorn a Fungal Food FavoriteNews
The meat substitute Quorn is derived from a fungus called Fusarium venenatum. A very similar fungus, F. graminearum, is one of the world's most damaging crop diseases. A new genome study shows why one fungus makes food, and the other destroys it.READ MORE
Neural Computer Hears Like HumansNews
Modelling the human senses is an incredibly complex task. Our brains arrange cells into complex hierarchies that process information from our surroundings. Now, a group at MIT have created a model of the human auditory cortex that can hear sounds and music in the same way that humans do.READ MORE
Stable Beta-Amyloid Dimers Identified in Alzheimer’s BrainsNews
A recent study exploited state-of-the-art mass spectrometry to provide the first direct evidence of beta-amyloid dimers in patients with Alzheimer’s disease and points to the potential of these molecules as biomarkers. Beta-amyloid dimers may be the smallest pathological species that trigger Alzheimer’s disease.
Comments | 0 ADD COMMENT
International Conference on Analytical and Bio Analytical Techniques
Oct 31 - Nov 01, 2018